Menu Search
Equities

MannKind Corp

MNKD:NMQ

MannKind Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.08
  • Today's Change-0.14 / -1.94%
  • Shares traded2.93m
  • 1 Year change+106.41%
  • Beta1.2952
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year MannKind Corp grew revenues 99.42% from 99.77m to 198.96m while net income improved from a loss of 87.40m to a smaller loss of 11.94m.
Gross margin71.91%
Net profit margin8.07%
Operating margin19.52%
Return on assets5.50%
Return on equity--
Return on investment7.00%
More ▼

Cash flow in USDView more

In 2023, MannKind Corp increased its cash reserves by 241.82%, or 168.71m. Cash Flow from Financing totalled 136.61m or 68.66% of revenues. In addition the company generated 34.09m in cash from operations while cash used for investing totalled 1.99m.
Cash flow per share0.0977
Price/Cash flow per share70.59
Book value per share-0.7612
Tangible book value per share-0.7875
More ▼

Balance sheet in USDView more

MannKind Corp appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load outweighs its assets and with an Interest Coverage ratio of only 0.720330000000000, earnings from day-to-day operations are not enough to service its debt. However, at this time, there are enough liquid assets to satisfy current obligations.
Current ratio4.54
Quick ratio4.17
Total debt/total equity--
Total debt/total capital1.77
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.